News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celldex Therapeutics, Inc. (CLDX) To Present Antibody-Drug Conjugate CDX-014 Preclinical Proof Of Concept Data At American Association for Cancer Research 2014


4/3/2014 12:08:25 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAMPTON, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1 (T cell immunoglobulin and mucin domain), which is upregulated in several cancers, including renal and ovarian carcinomas.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES